Methodology
The Luna Fit Score, explained
Programs in our Luna Fit rankings are scored out of 100 on the same six weighted factors — chosen and weighted for women considering GLP-1 care for PCOS, the perimenopause transition, or hormonal metabolic health. We apply the identical rubric to providers we earn a commission from and providers we don't. A score is our editorial judgment, built from each provider's public disclosures and our review. List order is a separate thing: providers we work with get a boost in the order and may appear first.
Other provider reviews describe care models, costs and limitations without assigning a score. Those reviews remain separate from our scored rankings.
The six factors
1. PCOS & hormonal suitability
22%How well the provider's approach fits women's hormonal metabolism — access to tirzepatide (often preferred where insulin resistance drives PCOS weight), awareness of androgens and cycle effects, and whether the program is built to treat more than a number on the scale. Our heaviest factor.
2. Clinical oversight & labs
20%Whether a licensed clinician — not just an intake form — stands behind the prescription, and whether the program runs or reviews labs. This matters more when hormones, thyroid and metabolic markers are in play.
3. Price transparency
18%The all-in monthly cost and, crucially, whether it's honest: no teaser first-month rate that silently triples, no hidden membership, lab or consult fees stacked on top.
4. Nationwide access
15%How many states are served and how quickly you reach a real prescriber and first dose — so care doesn't break if you move, travel, or live outside a metro.
5. Ongoing support
13%Quality of continuing care: side-effect and titration guidance, responsiveness, and whether support (and coaching, where offered) disappears once the first vial ships.
6. Cancellation fairness
12%How easily you can pause, switch or quit — and whether the provider locks you into contracts, auto-ships, or makes leaving deliberately painful.
One adjustment on top of the six
FDA warning letters
−8 ptsWhere a provider carries an FDA warning letter, we subtract 8 points from its “Clinical oversight & labs” score — the same deduction, applied the same way, to every provider that has one, whether or not we earn a commission from it. We say the letter exists and when it was issued, and we link FDA's own warning-letter database so you can read it yourself. We do not restate what the FDA alleged, and a letter does not remove a provider from this site: it is shown on that provider's own review, and you decide what to do with it.
How we stay honest
- Same rubric, commercial order. Programs in our rankings are graded on identical criteria, whether or not they pay us, and the score you see is that number. List order is commercial: partners get a ranking boost and may be placed first, and a featured partner can be placed above a higher-scoring provider.
- We name the limits. Most telehealth brands are general metabolic programs, not hormone clinics. Where the PCOS or perimenopause framing is broad rather than specialized, we say so and score it down.
- Facts are sourced, scores are judgment. Pricing, states served, and verification reflect each provider's public disclosures at last review; the weighted score is applied by the Luna Editorial Team, under our editorial policy.
- We re-check and log what changes. Telehealth pricing changes constantly. Each review shows the month it was last updated, and when a re-read corrects a price or plan we list it on our corrections page. Confirm current pricing on the provider's own site before deciding.
This page is editorial information, not medical advice. Compounded GLP-1 medications are not FDA-approved finished drug products, and GLP-1 medicines are not appropriate during pregnancy or while trying to conceive. Talk to a licensed clinician about your hormones, history and goals before starting any weight-management medication. See our affiliate disclosure and medical disclaimer.